Effects of dichloroacetate on the activation of the mitochondrial pathway in C6 cells in vitro

doi:10.5246/jcps.2011.05.058

Abstract

Abstract: Mitochondria are increasingly recognized as important targets for tumor treatment because of their central roles in apoptotic pathways and cellular metabolism. Dichloroacetate (DCA), a low molecular weight mitochondria-targeting agent, exhibits potential therapeutic effects for tumors. Based on the effects of DCA on tumor cellular metabolism, we carried out this study to investigate the anti-tumor activity of DCA in C6 glioma cells in vitro. The results showed that DCA was able to increase the activity of pyruvate dehydrogenase (PDH), induce the production of reactive oxygen species (ROS) and reduce the mitochondrial membrane potential (MMP) in C6 cells in vitro (P<0.05 or 0.01), indicating that the anti-tumor effects of DCA in C6 cells could be through the activation of the mitochondrial pathway. In conclusion, mitochondria could be a viable therapeutic target for the treatment of glioma.

Key words: Mitochondria metabolism, Dichloroacetate, C6 glioma, Pyruvate dehydrogenase, Reactive oxygen species, Mitochondrial membrane potential

CLC Number:

R962

Supporting:

Xin Zhao, Xin Wang, Ke-Fu Yu, Yu Duan, Jie-Si Li, Bing-Xiang Zhao, Xuan Zhang^*, Qiang Zhang. Effects of dichloroacetate on the activation of the mitochondrial pathway in C6 cells in vitro [J]. , DOI: 10.5246/jcps.2011.05.058.

References

[1] Pan, J.G.; Mak, T.W. Sci. STKE. 2007, 381, pe14.
[2] Samudio, I.; Fiegl, M.; Andreeff, M. Cancer Res. 2009, 69, 2163-2166.
[3] Pathania, D.; Millard, M.; Neamati, N. Adv. Drug Deliv. Rev. 2009, 61, 1250-1275.
[4] Warbrug, O. Science. 1956, 123, 309-314.
[5] Michelakis, E.D.; Webster, L.; Mackey, J.R. Br. J. Cancer. 2008, 99, 989-994.
[6] Yeung, S.J.; Pan, J.; Lee, M.H. Cell Mol. Life Sci. 2008, 65, 3981-3999.
[7] Fulda, S.; Galluzzi, L.; Kroemer, G. Nat. Rev. Drug Discov. 2010, 6, 447-464.
[8] Coude, F.X.; Saudubray, J.M.; DeMaugre, F.; Marsac, C.; Leroux, J.P.; Charpentier, C. N. Engl. J. Med. 1978, 299, 1365-1366.
[9] Stacpoole, P.W.; Wright, E.C.; Baumgartner, T.G.; Bersin, R.M.; Buchalter, S.; Curry, S.H.; Duncan, C.A.; Harman, E.M.; Henderson, G.N.; Jenkinson, S. N. Engl. J. Med. 1992, 327, 1564-1569.
[10] Bonnet, S.; Archer, S.L.; Allalunis-Turner, J.; Haromy, A.; Beaulieu, C.; Thompson, R.; Lee, C.T.; Lopaschuk, G.D.; Puttagunta, L.; Bonnet, S.; Harry, G.; Hashimoto, K.; Porter, C.J.; Andrade, M.A.; Thebaud, B.; Michelakis, E.D. Cancer Cell. 2007, 11, 37-51.
[11] Wong, J.Y.; Huggins, G.S.; Debidda, M.; Munshi, N.C. Gynecol. Oncol. 2008, 109, 394-402.
[12] Cao, W.; Yacoub, S.; Shiverick, K.T.; Namiki, K.; Sakai, Y.; Porvasnik, S.; Urbanek, C.; Rosser, C.J. Prostate. 2008, 68, 1223-1231.
[13] Kuroda, Y.; Toshima, K.; Watanabe, T.; Kobashi, H.; Ito, M.; Takeda, E.; Miyao, M. Pediatr. Res. 1984, 18, 936-938.
[14] Abemayor, E.; Kovachich, G.B.; Haugaard, N. J. Neurochem. 1984, 42, 38-42.
[15] Vichai, V.; Kirtikara, K. Nat. Protoc. 2006, 1, 1112-1126.
[16] Gohil, K.; Jones, D.A. Biosci. Rep. 1983, 3, 1-9.
[17] Kruger, N.J. Methods Mol. Biol. 1994, 32, 9-15.
[18] Lee, T.Y.; Chen, F.Y.; Chang, H.H.; Lin, H.C. Mol. Cell Biochem. 2009, 325, 53-59.
[19] Shanmugam, M.; McBrayer, S.K.; Rosen, S.T. Curr. Opin. Oncol. 2009, 21, 531-536.
[20] Stacpoole, P.W.; Henderson, G.N.; Yan, Z.; James, M.O. Environ. Health Perspect. 1998, 106, 989-994.